The Food and Drug Administration (FDA) has posted a discontinuation notice for Thyrolar (liotrix; Allergan) tablets, USP, ¼, ½, 1, 2, and 3 grains. The manufacturing discontinuation was a business decision made by the Company. 

Thyrolar contains triiodothyronine (T3 liothyronine) and tetraiodothyronine (T4 levothyroxine) and is indicated as replacement or supplemental therapy in patients with hypothyroidism, and as a pituitary thyroid stimulating hormone (TSH) suppressant, in the treatment or prevention of various types of euthyroid goiters, and in the management of thyroid cancer.

Related Articles

For more information call (800) 678-1605 or visit